Business Wire

TX-MAVENIR

25.8.2021 13:17:06 CEST | Business Wire | Press release

Share
Mavenir Acquires Telestax to Enhance Its Business Messaging and Customer Engagement Platform with CPaaS

Mavenir , the global leader in mobile messaging and business messaging monetization solutions for service providers, announced today that it has acquired Telestax Inc. , a leading global Communications Platform as a Service (CPaaS) enablement and application provider to the communications industry. This acquisition enhances Mavenir Engage , Mavenir’s omni-channel messaging monetization and customer engagement offerings by:

  • enabling service providers with new agile, nimble SaaS service models to better compete in the new digital economy
  • delivering specialization, flexibility, and simplicity to meet the needs of businesses of all sizes across a broad spectrum of industry verticals
  • providing service innovation and feature velocity with easy-to-consume APIs and business-critical applications

“Communication Platforms are becoming a key differentiator for service providers,” said Pardeep Kohli, President and CEO, Mavenir. “They will unlock enterprise value in 5G with API enablement for different verticals such as IoT, Smart Cities, Automotive and provide turnkey applications for logistics, fleet management, AI/ML chatbots, voice biometrics verification, immersive commerce/entertainment and many other use cases.”

“The early definition of CPaaS in terms of PSTN connectivity has been augmented to include a much broader range of services. Vendors that provide the full communication service stack – including the API layer and network infrastructure – have a competitive advantage from those whose strategy primarily focuses on the API layer and relies on partnerships to provide access to the network layer,”1 said Raúl Castañón-Martínez, Sr. Analyst, Workforce Productivity and Collaboration at 451 Research, a division of S&P Global Market Intelligence. According to 451 Research's Workforce Productivity & Collaboration 2021 CPaaS Market Monitor, total market revenue increased by well over 40% to $6.5bn in 2020, and will account for roughly $21bn in 2025, a CAGR of 26%.

“CPaaS is the key enabling technology for our Mavenir Engage service to position Communications Service Providers (CSPs) at the forefront of the digital engagement landscape,” said Ian Maclean, SVP/GM Cloud Services at Mavenir, “With this acquisition, Mavenir is lowering the barrier of entry and democratizing business messaging for businesses of all sizes to implement conversational commerce experiences.”

Mavenir Engage is Mavenir’s cloud-based messaging monetization and customer engagement offering that provides CSPs, systems integrators and channel partners with RCS Business Messaging (RBM), messaging monetization capabilities, chatbots, campaign management, and access to different messaging ecosystems—such as Google RCS Business Messaging.

Clark Peterson, Chairman, Cloud Communications Alliance, said: “Telestax has been a key partner to help drive the transformation of the CPaaS industry. Being part of the Mavenir family brings the breadth of portfolio to add new capabilities and further advance innovative customer offerings in Cloud Communications.”

Mavenir empowers service providers to give enterprises the ability to optimize workflows and customize business applications to better engage customers and employees. Eliminating complexity for their employees, increasing productivity and, most importantly, delighting their customers with a better customer experience.

Jean Deruelle, co-founder and CTO, Telestax, said: “From our roots as an Open-Source communications disruptor that defined the CPaaS Enablement Market with the Restcomm API framework, we are incredibly excited to join forces and combine our capabilities with Mavenir’s extensive 5G and omni-channel messaging portfolio in the next step of our journey to keep helping carriers globally define the future of business communications.”

About Mavenir

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

_____________________

1 451 Research, “Communications Platforms as a Service Market Guide 2021”

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye